Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

45.24
+0.16000.35%
Post-market: 45.240.00000.00%16:27 EDT
Volume:874.61K
Turnover:39.19M
Market Cap:3.60B
PE:-12.05
High:45.27
Open:44.86
Low:43.84
Close:45.08
Loading ...

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

Benzinga
·
27 Jan

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
27 Jan

Chinese AI Platform Fuels Jitters on Wall Street, Driving Premarket Losses for US Equity Futures

MT Newswires Live
·
27 Jan

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Benzinga
·
27 Jan

Akero Therapeutics MASH data ‘best-case-scenario,’ says Citi

TIPRANKS
·
27 Jan

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as China's DeepSeek Disrupts Tech Sector

MT Newswires Live
·
27 Jan

Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis

MT Newswires Live
·
27 Jan

Akero soars as drug shows it reverses scarring in liver disease patients

Reuters
·
27 Jan

Akero Therapeutics Shares Double After Positive Study Results for Efruxifermin

Dow Jones
·
27 Jan

Akero shares double after preliminary results from mid-stage trial for liver disease drug

Reuters
·
27 Jan

Akero Therapeutics Shares Double Pre-Bell After Preliminary Results From Phase 2b Trial of Lead Product Candidate

MT Newswires Live
·
27 Jan

Akero Therapeutics Shares Jump 91% Premarket After Co Reports Prelim Mid-Stage Data on Liver Disease Drug

THOMSON REUTERS
·
27 Jan

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to Mash—by Both Completer and ITT Analyses—at Week 96 in Phase 2B Symmetry Study

THOMSON REUTERS
·
27 Jan

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

GlobeNewswire
·
27 Jan

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

GlobeNewswire
·
25 Jan

Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan